New 'Living Drug' trial targets Tough-to-Treat ovarian cancer
NCT ID NCT07480954
Summary
This study is testing a new type of treatment called CAR-NK cell therapy for women with ovarian cancer that has come back or stopped responding to standard treatments. Doctors first check the patient's tumor for specific markers and then give them a personalized infusion of modified immune cells designed to attack those markers. The main goals are to see if the treatment is safe and if it can help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.